Antiphospholipid Syndrome, COVID-19
Conditions
Brief summary
Context: Until 70% of thrombotic event are reported during Sars-CoV2 infection. Antiphospholipid antibodies (aPL) tests are often positive. We aim to determine if aPL positivity is involved in thrombose of Sars-CoV2 infection investigating the effect of aPL on thrombin generation (TG) and leucocyte pathway activation (neutrophils extracellular traps (NETs) and activation of triggering receptor expressed on myeloid cells 1 (TREM-1)). Method: We will compare plasma from five groups of subjects: patients with antiphospholipid syndrome (APS) and patients hospitalized for Sars-CoV-2 infection with or without aPL, and as control, patients with acute venous thromboembolism event and healthy volunteers. For each subject, we will analyze aPL, activated protein C (APC) resistance measured by TG and leukocytes markers as circulating neutrophils extracellular traps (NETs) and soluble triggering receptor expressed on myeloid cells one (sTREM-1). We will control aPL test at three month and analyze their persistent positivity and association with thrombotic event. Results: we hypothesize that patients with COVID-19 and aPL will have a similar aPL and level of APS resistance that patients with APS. Also, we think that circulating NETs and sTREM-1 levels will be more important in patients with COVID-19 with aPL than patients without aPL and similar in patients with COVID-19 and aPL and patients with APS. Conclusion: our study will be the first to analyze the potential role of aPL on APC resistance measured by TG and neutrophil activation in COVID-19.
Interventions
DIAGNOSTIC_TESTcharacterization of aPL
characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patient receiving a comprehensive information about the study, and not opposed to participate \+ one criterion among : * patient hospitalized fo a COVID-19 * Patient with known APS * Patients hospitalized for an acute venous thromboembolism event aPL positivity or COVID-19 * healthy volunteers
Exclusion criteria
* For all participants : pregnancy, age below 18 years-old, absence of written informed consent , autoimmune or inflammatory disease except antiphospholipid syndrome * For patients with COVID-19: previous aPL positivity (before COVID-19 infection) * For patients with APS: previous symptomatic COVID-19 infection * For patients control with acute venous thromboembolism event: previous symptomatic COVID-19 infection, infection or inflammatory disease in flare at the time of thromboembolism event, known aPL positivity * For Healthy volunteers: history of thrombosis (venous, arterial or small vessels), previous symptomatic COVID-19 infection, infection or inflammatory disease in flare at the time of inclusion, known aPL positivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of activated protein C resistance and comparison between groups | at inclusion |
Secondary
| Measure | Time frame |
|---|---|
| frequency of positivity of each aPL test and comparison between groups | at inclusion |
| concentration of leucocytes activation markers and comparison between groups | at inclusion |
| frequency of persistent aPL test positivity and comparison between groups | at three month |
Countries
France
Contacts
Primary ContactVirginie DUFROST, MD
Backup ContactStephane Zuily, MD, PhD
Outcome results
None listed